Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Med Spas: Peptide Do's and Do Not's

Client Alert

Recent Ohio Board of Pharmacy (“BOP”) guidance has highlighted compliance considerations surrounding the use of peptides in med spas.  Owners and operators of med spas will want to keep these considerations in mind as the use of peptides, especially GLP-1 medications, expands.  

Certain peptide drugs are FDA approved medications and can be used in med spas. However, not every peptide-based drug is created equal or is approval by the FDA. According to BOP guidance, some peptides, such as Retatrutide, are not currently FDA approved.[1] In addition, many peptide-based drugs, such as Semaglutide or BPC-157 peptides, cannot currently be compounded.[2]

The BOP conducts regular inspections of med spas and has revoked or suspended several med-spa’s TDDD licenses for violations surrounding the use of peptides. The most common violations are purchasing medication from an unlicensed seller, purchasing and utilizing medication marked “for research purposes only,” purchasing non-FDA approved medication, and obtaining foreign sourced medication.   

When determining which peptides your med-spa can utilize, it is important to keep the following considerations in mind:

  • Only use peptides that are FDA approved.
  • Do not purchase peptides from unlicensed sellers.
  • Do not use peptides labeled “for research purposes only.”
  • Ensure compliance with compounding requirements, including not making prohibited copies of peptides.
  • Properly store any peptides prior to their use.

If you have questions regarding BOP compliance or how using peptides may impact your practice, please contact BMD Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001.     


[1] Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

[1] Ten Common Prescriber Clinic and Medical Spa Violations, Ohio Board of Pharmacy, last accessed April 23, 2026. See also, Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.


Compounding GLP-1 Drugs - Recent Updates

Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.

Top Compliance Risks for Ohio Med-Spas in 2025

The Ohio Board of Pharmacy has increased inspections of med-spas holding Terminal Distributor of Dangerous Drugs (TDDD) licenses, with many facing enforcement actions in 2025. Common issues include purchasing from unlicensed distributors, improper drug storage, inadequate recordkeeping, and insufficient prescriber oversight. Understanding these risks and maintaining compliance can help protect your practice from penalties and license suspension.

Pre and Postnuptial Agreements | Necessary, Maybe, What Happened to Forever?

Both Florida and Ohio now allow clients to enter into a prenuptial or postnuptial agreement prior to marriage or after marriage (Ohio previously did not allow postnuptial agreements). Both documents have statutory guidelines that must be followed in terms of execution and financial disclosure.

DHS Ends All Employment Authorization Auto-Extensions

Effective October 30, 2025, DHS ends all automatic work authorization renewals. The 540-day extension applies only to renewals filed before this date, and there is no grace period for expired EADs filed on or after October 30. Employers must audit EADs, train staff, ensure I-9 compliance, and plan for work authorization gaps. Penalties for noncompliance can be severe.

CMS’s Rural Health Funding Announcement

CMS has announced a $50 billion Rural Health Transformation (RHT) Program to improve healthcare access, quality, and outcomes in rural communities. All states are eligible to apply for funding by November 5, 2025. Half of the funds will be distributed equally, with the remainder based on state-specific factors. The program supports evidence-based initiatives, workforce recruitment, and access to treatment services, with awards assessed annually